Logo Université Laval Logo Université Laval Logo Université Laval

Découvrez nos professeurs et professeures!

Jacques Simard

Vice-doyen

Jacques Simard
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie
Santé des populations et pratiques optimales en santé
Bioinformatique / données massives (big data)
Transfert des connaissances

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer du sein
  • Cancer héréditaire
  • Cancers hormonaux-dépendants
  • Génétique du cancer
Génétique humaine
  • Gènes de susceptibilité
  • Génétique et éthique
  • Génétique moléculaire
  • Génomique
  • Polymorphisme
Santé des populations
Services de santé
Génomique et protéomique

Projets de recherche

  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Observatoire international sur les impacts sociétaux de l'intelligence artificielle et du numérique - Fonds de recherche du Québec - Société et culture, Université Laval - Fonds internes - Appel à propositions : création d’un Observatoire international sur les impacts sociétaux de l’intelligence artificielle et du numérique, co-chercheur - 2018-04-01 au 2024-03-31
  • From correlation to causation in genomics: identifying mechanisms underlying disease - Instituts de recherche en santé du Canada - Subventions Fondation, University of Toronto, co-chercheur - 2015-07-01 au 2022-06-30
  • Chaire de recherche du Canada en oncogénétique - Instituts de recherche en santé du Canada - Chaires de recherche du Canada - Fonctionnement, chercheur principal - 2015-03-01 au 2022-06-30
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activités 3.1/3.2 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente - Fonds de recherche du Québec - Santé, co-chercheur - 2020-04-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : R92 - Transferts de fonds interinstitutions - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 5 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 3.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 2.3 - Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.2 - Instituts de recherche en santé du Canada, Génome Québec - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) : Activité 1.1 - Génome Québec, Instituts de recherche en santé du Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Fonds Merck - Contribution FMed (50%) salaire chercheurs-boursiers qui retardent demande FRQS J2 d'une année. - Fondation de l'Université Laval, chercheur principal - 2017-04-01 au 2022-03-31
  • Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II) - Regroupement de compagnies et corporations canadiennes, Fondation du CHU de Québec, Génome Québec, Ministère de la santé (Ontario), Ministère de l'Économie, de la Science et de l'Innovation, Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Génome Canada - Projets de recherche appliquée à grande échelle - Large-Scale Applied Research Project, chercheur principal - 2017-11-01 au 2022-03-31
  • Journée de la recherche de la Faculté de médecine - Université Laval - Fonds internes - Fonds général de recherche du CRSNG, co-chercheur - 2010-11-24 au 2020-03-31
  • Impacts of evolving demography and socio-economic status on assessment of genetic risks - Conseil de recherches en sciences humaines du Canada - Programme Savoir: Subventions Savoir, Université d'Ottawa, co-chercheur - 2017-04-01 au 2020-03-31
  • Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST) - Commission européenne - Programme-cadre pour le recherche et l'innovation: Horizon 2020, Netherlands Cancer Institute (The), co-chercheur - 2015-01-09 au 2020-01-08
  • Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) - Commission européenne - Programme-cadre pour le recherche et l'innovation: Horizon 2020, Leiden University, co-chercheur - 2015-01-09 au 2020-01-08
  • GE3LS Network in genomics and personalized health - Génome Canada, University of Alberta, co-chercheur - 2016-01-01 au 2019-12-31

Publications

  • Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History., , Journal of the National Cancer Institute, 2021, 10.1093/jnci/djaa127
  • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers., , Nature communications, 2021, 10.1038/s41467-020-20496-3
  • Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada., , Journal of personalized medicine, 2021, 10.3390/jpm11020095
  • CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers., , British journal of cancer, 2021, 10.1038/s41416-020-01185-w
  • Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study., , American journal of obstetrics and gynecology, 2021, 10.1016/j.ajog.2021.01.014
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women., , The New England journal of medicine, 2021, 10.1056/nejmoa1913948
  • Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers, Yan Dora Zhang, Amber N. Hurson, Haoyu Zhang, Parichoy Pal Choudhury, Douglas F. Easton, Roger L. Milne, Jacques Simard, Per Hall, Kyriaki Michailidou, Joe Dennis, Marjanka K. Schmidt, Jenny Chang-Claude, Puya Gharahkhani, David Whiteman, Peter T. Campbell, Michael Hoffmeister, Mark Jenkins, Ulrike Peters, Li Hsu, Stephen B. Gruber, Graham Casey, Stephanie L. Schmit, Tracy A. O’Mara, Amanda B. Spurdle, Deborah J. Thompson, Ian Tomlinson, Immaculata De Vivo, Maria Teresa Landi, Matthew H. Law, Mark M. Iles, Florence Demenais, Rajiv Kumar, Stuart MacGregor, D. Timothy Bishop, Sarah V. Ward, Melissa L. Bondy, Richard Houlston, John K. Wiencke, Beatrice Melin, Jill Barnholtz-Sloan, Ben Kinnersley, Margaret R. Wrensch, Christopher I. Amos, Rayjean J. Hung, Paul Brennan, James McKay, Neil E. Caporaso, Sonja I. Berndt, Brenda M. Birmann, Nicola J. Camp, Peter Kraft, Nathaniel Rothman, Susan L. Slager, Andrew Berchuck, Paul D. P. Pharoah, Thomas A. Sellers, Simon A. Gayther, Celeste L. Pearce, Ellen L. Goode, Joellen M. Schildkraut, Kirsten B. Moysich, Laufey T. Amundadottir, Eric J. Jacobs, Alison P. Klein, Gloria M. Petersen, Harvey A. Risch, Rachel Z. Stolzenberg-Solomon, Brian M. Wolpin, Donghui Li, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote-Jarai, Fredrick R. Schumacher, Ali Amin Al Olama, Mark P. Purdue, Ghislaine Scelo, Marlene D. Dalgaard, Mark H. Greene, Tom Grotmol, Peter A. Kanetsky, Katherine A. McGlynn, Katherine L. Nathanson, Clare Turnbull, Fredrik Wiklund, Douglas F. Easton, Roger L. Milne, Jacques Simard, Per Hall, Kyriaki Michailidou, Joe Dennis, Marjanka K. Schmidt, Jenny Chang-Claude, Puya Gharahkhani, David Whiteman, Peter T. Campbell, Michael Hoffmeister, Mark Jenkins, Ulrike Peters, Li Hsu, Stephen B. Gruber, Graham Casey, Stephanie L. Schmit, Peter T. Campbell, Michael Hoffmeister, Mark Jenkins, Ulrike Peters, Li Hsu, Stephen B. Gruber, Graham Casey, Stephanie L. Schmit, Tracy A. O’Mara, Amanda B. Spurdle, Deborah J. Thompson, Ian Tomlinson, Immaculata De Vivo, Peter T. Campbell, Michael Hoffmeister, Mark Jenkins, Ulrike Peters, Li Hsu, Stephen B. Gruber, Graham Casey, Stephanie L. Schmit, Maria Teresa Landi, Matthew H. Law, Mark M. Iles, Florence Demenais, Rajiv Kumar, Stuart MacGregor, David T. Bishop, Sarah V. Ward, Melissa L. Bondy, Richard Houlston, John K. Wiencke, Beatrice Melin, Jill Barnholtz-Sloan, Ben Kinnersley, Margaret R. Wrensch, Christopher I. Amos, Rayjean J. Hung, Paul Brennan, James McKay, Neil E. Caporaso, Christopher I. Amos, Rayjean J. Hung, Paul Brennan, James McKay, Neil E. Caporaso, Sonja I. Berndt, Brenda M. Birmann, Nicola J. Camp, Peter Kraft, Nathaniel Rothman, Susan L. Slager, Andrew Berchuck, Paul D. P. Pharoah, Thomas A. Sellers, Simon A. Gayther, Celeste L. Pearce, Ellen L. Goode, Joellen M. Schildkraut, Kirsten B. Moysich, Christopher I. Amos, Paul Brennan, James McKay, Laufey T. Amundadottir, Eric J. Jacobs, Alison P. Klein, Gloria M. Petersen, Harvey A. Risch, Rachel Z. Stolzenberg-Solomon, Brian M. Wolpin, Donghui Li, Laufey T. Amundadottir, Eric J. Jacobs, Alison P. Klein, Gloria M. Petersen, Harvey A. Risch, Rachel Z. Stolzenberg-Solomon, Brian M. Wolpin, Donghui Li, Rosalind A. Eeles, Christopher A. Haiman, Zsofia Kote-Jarai, Fredrick R. Schumacher, Ali Amin Al Olama, Mark P. Purdue, Ghislaine Scelo, Marlene D. Dalgaard, Mark H. Greene, Tom Grotmol, Peter A. Kanetsky, Katherine A. McGlynn, Katherine L. Nathanson, Clare Turnbull, Fredrik Wiklund, Stephen J. Chanock, Nilanjan Chatterjee, Montserrat Garcia-Closas, Nature Communications, 2020, 10.1038/s41467-020-16483-3
  • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer, Taru A. Muranen, Sofia Khan, Rainer Fagerholm, Kristiina Aittomäki, Julie M. Cunningham, Joe Dennis, Goska Leslie, Lesley McGuffog, Michael T. Parsons, Jacques Simard, Susan Slager, Penny Soucy, Douglas F. Easton, Marc Tischkowitz, Amanda B. Spurdle, Rita K. Schmutzler, Barbara Wappenschmidt, Eric Hahnen, Maartje J. Hooning, Christian F. Singer, Gabriel Wagner, Mads Thomassen, Inge Sokilde Pedersen, Susan M. Domchek, Katherine L. Nathanson, Conxi Lazaro, Caroline Maria Rossing, Irene L. Andrulis, Manuel R. Teixeira, Paul James, Judy Garber, Jeffrey N. Weitzel, Anna Jakubowska, Drakoulis Yannoukakos, Esther M. John, Melissa C. Southey, Marjanka K. Schmidt, Antonis C. Antoniou, Georgia Chenevix-Trench, Carl Blomqvist, Heli Nevanlinna, npj Breast Cancer, 2020, 10.1038/s41523-020-00185-6
  • PALB2 Variants: Protein Domains and Cancer Susceptibility., , Trends in cancer, 2020, 10.1016/j.trecan.2020.10.002
  • Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)., , JAMA oncology, 2020, 10.1001/jamaoncol.2020.2134
  • European polygenic risk score for prediction of breast cancer shows similar performance in Asian women., , Nature communications, 2020, 10.1038/s41467-020-17680-w
  • Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants., , Genetics in medicine : official journal of the American College of Medical Genetics, 2020, 10.1038/s41436-020-0862-x
  • Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction., , Biostatistics (Oxford, England), 2020, 10.1093/biostatistics/kxy075
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement., , Nature reviews. Clinical oncology, 2020, 10.1038/s41571-020-0388-9
  • Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk., , Scientific reports, 2020, 10.1038/s41598-020-65665-y
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses., , Nature genetics, 2020, 10.1038/s41588-020-0609-2
  • Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants., , Nature communications, 2020, 10.1038/s41467-020-15046-w
  • Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent., , Journal of the National Cancer Institute, 2020, 10.1093/jnci/djz109
  • Transcriptome-wide association study of breast cancer risk by estrogen-receptor status., , Genetic epidemiology, 2020, 10.1002/gepi.22288
  • A network analysis to identify mediators of germline-driven differences in breast cancer prognosis., , Nature communications, 2020, 10.1038/s41467-019-14100-6
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers., , Breast cancer research : BCR, 2020, 10.1186/s13058-020-1247-4
  • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes., , Nature genetics, 2020, 10.1038/s41588-019-0537-1
  • Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-19-0546
  • Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2., , Nature communications, 2019, 10.1038/s41467-019-13194-2
  • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness., , Cancer research, 2019, 10.1158/0008-5472.can-19-1840
  • A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor., , Nucleic acids research, 2019, 10.1093/nar/gkz780
  • Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives., , Healthcare policy = Politiques de sante, 2019, 10.12927/hcpol.2019.26072
  • The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer., , NPJ breast cancer, 2019, 10.1038/s41523-019-0127-5
  • Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers., , Journal of community genetics, 2019, 10.1007/s12687-019-00438-3
  • Functional characterization of 84 PALB2 variants of uncertain significance., , Genetics in medicine : official journal of the American College of Medical Genetics, 2019, 10.1038/s41436-019-0682-z
  • Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry., , EBioMedicine, 2019, 10.1016/j.ebiom.2019.09.006
  • Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk., , International journal of epidemiology, 2019, 10.1093/ije/dyz047
  • Two truncating variants in FANCC and breast cancer risk., , Scientific reports, 2019, 10.1038/s41598-019-48804-y
  • Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk., , International journal of cancer, 2019, 10.1002/ijc.32542
  • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers., , British journal of cancer, 2019, 10.1038/s41416-019-0492-8
  • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis., , International journal of epidemiology, 2019, 10.1093/ije/dyy201
  • Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer., , Nature communications, 2019, 10.1038/s41467-018-08053-5
  • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study., , Journal of the National Cancer Institute, 2019, 10.1093/jnci/djy132
  • Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control., , Genes, 2019, 10.3390/genes10030186
  • Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease., , Public health reviews, 2019, 10.1186/s40985-019-0111-5
  • A response to "Personalised medicine and population health: breast and ovarian cancer"., , Human genetics, 2019, 10.1007/s00439-019-01984-z
  • Genome-wide association study of germline variants and breast cancer-specific mortality., , British journal of cancer, 2019, 10.1038/s41416-019-0393-x
  • The association between weight at birth and breast cancer risk revisited using Mendelian randomisation., , European journal of epidemiology, 2019, 10.1007/s10654-019-00485-7
  • Shared heritability and functional enrichment across six solid cancers., , Nature communications, 2019, 10.1038/s41467-018-08054-4
  • BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors., , Genetics in medicine : official journal of the American College of Medical Genetics, 2019, 10.1038/s41436-018-0406-9
  • Open-Science Precision Medicine in Canada: Points to Con, , FACETS, 2019, https://doi.org/10.1139/facets-2018-0034
  • The Tumor Suppressor PALB2: Inside Out., , Trends in biochemical sciences, 2019, 10.1016/j.tibs.2018.10.008
  • DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness., , Frontiers in genetics, 2019, 10.3389/fgene.2019.01349
  • Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening., , New Genetics and Society, 2019, doi: 10.1080/14636778.2018.1549477
  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes., , American journal of human genetics, 2018, 10.1016/j.ajhg.2018.11.002
  • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation., , EMBO molecular medicine, 2018, 10.15252/emmm.201809172
  • The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations., , JNCI cancer spectrum, 2018, 10.1093/jncics/pky078
  • Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort., , International journal of cancer, 2018, 10.1002/ijc.31841
  • Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer., , Cancer research, 2018, 10.1158/0008-5472.can-18-1018
  • A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk., , Cancer research, 2018, 10.1158/0008-5472.can-18-0951
  • A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer., , Nature genetics, 2018, 10.1038/s41588-018-0132-x
  • Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study., , JNCI cancer spectrum, 2018, 10.1093/jncics/pky023
  • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations., , Human mutation, 2018, 10.1002/humu.23406
  • Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada)., , BMJ open, 2018, 10.1136/bmjopen-2017-016662
  • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families., , Current oncology (Toronto, Ont.), 2017, 10.3747/co.24.3759
  • Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?, , American journal of preventive medicine, 2017, 10.1016/j.amepre.2017.05.016
  • Association analysis identifies 65 new breast cancer risk loci., , Nature, 2017, 10.1038/nature24284
  • Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer., , Nature genetics, 2017, 10.1038/ng.3785
  • PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1., , Oncotarget, 2017, 10.18632/oncotarget.21800
  • Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia., , Journal of medical genetics, 2017, 10.1136/jmedgenet-2017-104947
  • Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers., , Frontiers in genetics, 2017, 10.3389/fgene.2017.00128
  • Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families., , Oncotarget, 2017, 10.18632/oncotarget.20219
  • Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium., , International journal of cancer, 2017, 10.1002/ijc.30859
  • Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers., , Journal of the National Cancer Institute, 2017, 10.1093/jnci/djw302
  • On the readiness of physicians for pharmacogenomics testing: an empirical assessment., , The pharmacogenomics journal, 2017, 10.1038/tpj.2017.22
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers., , JAMA, 2017, 10.1001/jama.2017.7112
  • Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores., , Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 10.1200/jco.2016.69.4935
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer., , Nature genetics, 2017, 10.1038/ng.3826
  • Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?, , Familial cancer, 2017, 10.1007/s10689-016-9920-6
  • Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies., , Current oncology (Toronto, Ont.), 2016, 10.3747/co.23.2961
  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry., , Breast cancer research : BCR, 2016, 10.1186/s13058-016-0786-1
  • Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21., , Oncotarget, 2016, 10.18632/oncotarget.12818
  • rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk., , Scientific reports, 2016, 10.1038/srep36874
  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women., , Breast cancer research : BCR, 2016, 10.1186/s13058-016-0768-3
  • Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3., , Breast cancer research and treatment, 2016, 10.1007/s10549-016-4018-2
  • Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016, 10.1158/1055-9965.epi-16-0735
  • The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016, 10.1158/1055-9965.epi-16-0106
  • Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation., , American journal of human genetics, 2016, 10.1016/j.ajhg.2016.07.017
  • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)., , Scientific reports, 2016, 10.1038/srep32512
  • Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus., , Nature communications, 2016, 10.1038/ncomms12675
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS., , Journal of medical genetics, 2016, 10.1136/jmedgenet-2016-103839
  • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus., , PloS one, 2016, 10.1371/journal.pone.0160316
  • Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent., , PLoS medicine, 2016, 10.1371/journal.pmed.1002105
  • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers., , PloS one, 2016, 10.1371/journal.pone.0158801
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types., , Cancer discovery, 2016, 10.1158/2159-8290.cd-15-1227
  • An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression., , Human molecular genetics, 2016, 10.1093/hmg/ddw223
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus., , Breast cancer research : BCR, 2016, 10.1186/s13058-016-0718-0
  • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer., , International journal of cancer, 2016, 10.1002/ijc.30150
  • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers., , Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes, 2016, 10.1016/j.carj.2015.12.003
  • ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry., , PloS one, 2016, 10.1371/journal.pone.0156820
  • RAD51B in Familial Breast Cancer., , PloS one, 2016, 10.1371/journal.pone.0153788
  • Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer., , Nature communications, 2016, 10.1038/ncomms11375
  • Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model., , Genetics in medicine : official journal of the American College of Medical Genetics, 2016, 10.1038/gim.2016.31
  • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry., , Cancer causes & control : CCC, 2016, 10.1007/s10552-016-0741-6
  • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170., , Nature genetics, 2016, 10.1038/ng.3521
  • Genetic predisposition to ductal carcinoma in situ of the breast., , Breast cancer research : BCR, 2016, 10.1186/s13058-016-0675-7
  • The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes., , Familial cancer, 2016, 10.1007/s10689-015-9835-7
  • Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium., , Human genetics, 2015, 10.1007/s00439-015-1616-8
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers., , Journal of the National Cancer Institute, 2015, 10.1093/jnci/djv315
  • Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation., , Genetics in medicine : official journal of the American College of Medical Genetics, 2015, 10.1038/gim.2015.135
  • SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival., , Oncotarget, 2015, 10.18632/oncotarget.4991
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair., , Nature genetics, 2015, 10.1038/ng.3412
  • Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, 10.1158/1055-9965.epi-15-0363
  • SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation., , Genetic epidemiology, 2015, 10.1002/gepi.21914
  • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization., , Journal of the National Cancer Institute, 2015, 10.1093/jnci/djv219
  • Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project, , Advances in Genomics and Genetics, 2015, https://doi.org/10.2147/AGG.S66286
  • Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression., , American journal of human genetics, 2015, 10.1016/j.ajhg.2015.05.002
  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer., , Gynecologic oncology, 2015, 10.1016/j.ygyno.2015.04.034
  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers., , Breast cancer research : BCR, 2015, 10.1186/s13058-015-0567-2
  • Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures., , Cancer research, 2015, 10.1158/0008-5472.can-14-2012
  • Prediction of breast cancer risk based on profiling with common genetic variants., , Journal of the National Cancer Institute, 2015, 10.1093/jnci/djv036
  • Analysis of multivariate failure times in the presence of selection bias with application to breast cancer, , 2015, doi: 10.1111/rssc.12091
  • Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers., , PloS one, 2015, 10.1371/journal.pone.0120020
  • Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer., , JAMA, 2015, 10.1001/jama.2014.5985
  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer., , Nature genetics, 2015, 10.1038/ng.3242
  • Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2., , Human molecular genetics, 2015, 10.1093/hmg/ddv035
  • Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer., , Carcinogenesis, 2015, 10.1093/carcin/bgu326
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer., , Nature genetics, 2015, 10.1038/ng.3185
  • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers., , Breast cancer research : BCR, 2014, 10.1186/s13058-014-0492-9
  • Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1., , American journal of human genetics, 2014, 10.1016/j.ajhg.2014.11.009
  • MicroRNA related polymorphisms and breast cancer risk., , PloS one, 2014, 10.1371/journal.pone.0109973
  • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014, 10.1158/1055-9965.epi-14-0532
  • Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation., , Nature communications, 2014, 10.1038/ncomms5999
  • Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk., , Human molecular genetics, 2014, 10.1093/hmg/ddu431
  • Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings., , Public health genomics, 2014, 10.1159/000362358
  • Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium., , Human molecular genetics, 2014, 10.1093/hmg/ddu311
  • Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade., , Human molecular genetics, 2014, 10.1093/hmg/ddu300
  • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study., , Breast cancer research : BCR, 2014, 10.1186/bcr3662
  • Genetic predisposition to in situ and invasive lobular carcinoma of the breast., , PLoS genetics, 2014, 10.1371/journal.pgen.1004285
  • DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers., , PLoS genetics, 2014, 10.1371/journal.pgen.1004256
  • FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium., , British journal of cancer, 2014, 10.1038/bjc.2013.769
  • Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1., , American journal of human genetics, 2013, 10.1016/j.ajhg.2013.10.026
  • Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions., , Genetic epidemiology, 2013, 10.1002/gepi.21771
  • A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium., , Human molecular genetics, 2013, 10.1093/hmg/ddt581
  • Lessons learned and challenges posed in cancer genetics. Introduction., , Journal of internal medicine, 2013, 10.1111/joim.12129
  • Life insurance: genomic stratification and risk classification., , European journal of human genetics : EJHG, 2013, 10.1038/ejhg.2013.228
  • Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers., , Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, 10.1200/jco.2012.47.8313
  • COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration., , Breast cancer research : BCR, 2013, 10.1186/bcr3434
  • Genome-wide association studies identify four ER negative-specific breast cancer risk loci., , Nature genetics, 2013, 10.1038/ng.2561
  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk., , Nature genetics, 2013, 10.1038/ng.2563
  • Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer., , Nature genetics, 2013, 10.1038/ng.2566
  • Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers., , American journal of human genetics, 2013, 10.1016/j.ajhg.2013.01.002
  • Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk., , PLoS genetics, 2013, 10.1371/journal.pgen.1003212
  • Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk., , PLoS genetics, 2013, 10.1371/journal.pgen.1003173
  • Genetic discrimination and life insurance: a systematic review of the evidence., , BMC medicine, 2013, 10.1186/1741-7015-11-25
  • Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk., , European journal of human genetics : EJHG, 2013, 10.1038/ejhg.2012.286
  • Family communication following BRCA1/2 genetic testing: a close look at the process., , Journal of genetic counseling, 2012, 10.1007/s10897-012-9559-x
  • A focus group study on breast cancer risk presentation: one format does not fit all., , European journal of human genetics : EJHG, 2012, 10.1038/ejhg.2012.248
  • Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers., , Breast cancer research and treatment, 2012, 10.1007/s10549-012-2255-6
  • Legal liability and the uncertain nature of risk prediction: the case of breast cancer risk prediction models., , Public health genomics, 2012, 10.1159/000342138
  • Life events may contribute to family communication about cancer risk following BRCA1/2 testing., , Journal of genetic counseling, 2012, 10.1007/s10897-012-9531-9
  • Functional analysis of promoter variants in KU70 and their role in cancer susceptibility., , Genes, chromosomes & cancer, 2012, 10.1002/gcc.21983
  • Personalized medicine and access to health care: potential for inequitable access?, , European journal of human genetics : EJHG, 2012, 10.1038/ejhg.2012.149
  • Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population., , International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, 10.1097/igc.0b013e318257b936
  • A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012, 10.1158/1055-9965.epi-12-0229
  • Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study., , British journal of cancer, 2012, 10.1038/bjc.2012.160
  • Self-reported mammography use following BRCA1/2 genetic testing may be overestimated., , Familial cancer, 2012, 10.1007/s10689-011-9490-6
  • Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers., , Breast cancer research : BCR, 2012, 10.1186/bcr3121
  • Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012, 10.1158/1055-9965.epi-11-0888
  • Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers., , Human mutation, 2012, 10.1002/humu.22025
  • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011, 10.1158/1055-9965.epi-11-0775
  • ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes., , Human mutation, 2011, 10.1002/humu.21628
  • Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2., , Breast cancer research : BCR, 2011, 10.1186/bcr3052
  • Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study., , Genetics in medicine : official journal of the American College of Medical Genetics, 2011, 10.1038/gim.0b013e3182310a7f
  • Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers., , Human molecular genetics, 2011, 10.1093/hmg/ddr388
  • Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers., , Human molecular genetics, 2011, 10.1093/hmg/ddr226
  • Systematic mixed-methods reviews are not ready to be assessed with the available tools., , Journal of clinical epidemiology, 2011, 10.1016/j.jclinepi.2011.01.002
  • Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility., , Psycho-oncology, 2011, 10.1002/pon.1936
  • Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec., , European journal of human genetics : EJHG, 2011, 10.1038/ejhg.2010.227
  • Return of research results: general principles and international perspectives., , The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2011, 10.1111/j.1748-720x.2011.00625.x
  • Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers., , Journal of the National Cancer Institute, 2010, 10.1093/jnci/djq494
  • Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction., , Cancer research, 2010, 10.1158/0008-5472.can-10-1907
  • Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010, 10.1158/1055-9965.epi-10-0517
  • A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population., , Nature genetics, 2010, 10.1038/ng.669
  • The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers., , Breast cancer research and treatment, 2010, 10.1007/s10549-010-1123-5
  • Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer., , Genetic testing and molecular biomarkers, 2010, 10.1089/gtmb.2010.0027
  • Genetic testing, physicians and the law: will the tortoise ever catch up with the hare?, , Annals of health law, 2010
  • Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers., , Breast cancer research and treatment, 2009, 10.1007/s10549-009-0601-0
  • Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)., , British journal of cancer, 2009, 10.1038/sj.bjc.6605416
  • The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers., , British journal of cancer, 2009, 10.1038/sj.bjc.6605279
  • Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers., , Human molecular genetics, 2009, 10.1093/hmg/ddp372
  • Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer., , BMC cancer, 2009, 10.1186/1471-2407-9-181
  • Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer., , The Journal of steroid biochemistry and molecular biology, 2009, 10.1016/j.jsbmb.2009.05.005
  • Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009, 10.1158/1055-9965.epi-08-0546
  • No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study., , Breast cancer research and treatment, 2008, 10.1007/s10549-008-0064-8
  • Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population., , Journal of genetic counseling, 2008, 10.1007/s10897-008-9150-7
  • Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families., , Journal of human genetics, 2008, 10.1007/s10038-008-0285-z
  • Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer., , Journal of molecular endocrinology, 2008, 10.1677/jme-07-0101
  • Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers., , American journal of human genetics, 2008, 10.1016/j.ajhg.2008.02.008
  • Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer., , Journal of human genetics, 2008, 10.1007/s10038-008-0276-0
  • Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families., , International journal of cancer, 2008, 10.1002/ijc.23058
  • Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer., , The Journal of steroid biochemistry and molecular biology, 2007, 10.1016/j.jsbmb.2007.10.004
  • Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer., , Journal of human genetics, 2007, 10.1007/s10038-007-0203-9
  • RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies., , American journal of human genetics, 2007, 10.1086/522611
  • Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families., , Familial cancer, 2007, 10.1007/s10689-007-9151-y
  • Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group., , Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, 10.1200/jco.2007.11.1179
  • AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, 10.1158/1055-9965.epi-07-0129
  • Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, 10.1158/1055-9965.epi-06-0829
  • An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)., , Breast cancer research : BCR, 2007, 10.1186/bcr1670
  • Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation., , Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2007, 10.1016/s1701-2163(16)32349-0
  • Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, 10.1158/1055-9965.epi-06-0340
  • Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling., , Genetic testing, 2007, 10.1089/gte.2006.9998
  • Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families., , BMC cancer, 2006, 10.1186/1471-2407-6-230
  • Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics., , Human genetics, 2006, 10.1007/s00439-006-0219-9
  • Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer., , Journal of medical genetics, 2006, 10.1136/jmg.2006.044388
  • The emergence of an ethical duty to disclose genetic research results: international perspectives., , European journal of human genetics : EJHG, 2006, 10.1038/sj.ejhg.5201690
  • Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group., , Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, 10.1200/jco.2005.03.3126
  • Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility., , Psychological reports, 2006, 10.2466/pr0.98.3.873-881
  • Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)., , Journal of the National Cancer Institute, 2006, 10.1093/jnci/djj132
  • Guidelines for disclosing genetic information to family members: from development to use., , Familial cancer, 2006, 10.1007/s10689-005-2581-5
  • No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families., , Genetic testing, 2006, 10.1089/gte.2006.10.104
  • Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges., , Familial cancer, 2006, 10.1007/s10689-005-2570-8
  • The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, 10.1158/1055-9965.epi-05-0709
  • Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility., , Nutrition and cancer, 2006, 10.1207/s15327914nc5402_1
  • BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families., , Breast cancer research : BCR, 2005, 10.1186/bcr1365
  • No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, 10.1158/1055-9965.epi-05-0512
  • CYP17 and breast cancer: no overall effect, but what about interactions?, , Breast cancer research : BCR, 2005, 10.1186/bcr1320
  • A new alternative splice variant of BRCA1 containing an additional in-frame exon., , Biochimica et biophysica acta, 2005, 10.1016/j.bbaexp.2005.08.011
  • A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics., , American journal of human genetics, 2005, 10.1086/432377
  • Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families., , Human genetics, 2005, 10.1007/s00439-005-1297-9
  • Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13., , The Prostate, 2005, 10.1002/pros.20198
  • HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results., , Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2005, 10.1016/s1701-2163(16)30455-8
  • Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005, 10.1158/1055-9965.epi-04-0202
  • Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2005
  • Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy., , Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2004, 10.1016/s1701-2163(16)30432-7
  • Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2., , Biochimica et biophysica acta, 2004, 10.1016/j.bbaexp.2004.07.001
  • Physicians, genetics and life insurance., , CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, 10.1503/cmaj.1040127
  • Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?, , Cancer research, 2004, 10.1158/0008-5472.can-03-2678
  • Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium., , The Prostate, 2003, 10.1002/pros.10301
  • Prostate cancer susceptibility genes: lessons learned and challenges posed., , Endocrine-related cancer, 2003, 10.1677/erc.0.0100225
  • BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations., , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003
  • Genomic organization and expression of the mouse Brca2 gene., , Mammalian genome : official journal of the International Mammalian Genome Society, 2002, 10.1007/s00335-002-2300-6
  • Perspective: prostate cancer susceptibility genes., , Endocrinology, 2002, 10.1210/endo.143.6.8890
  • Support groups for people carrying a BRCA mutation., , CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001
  • A candidate prostate cancer susceptibility gene at chromosome 17p., , Nature genetics, 2001, 10.1038/84808
  • High risk genes predisposing to prostate cancer development-do they exist?, , Prostate cancer and prostatic diseases, 2000, 10.1038/sj.pcan.4500478
  • Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators., , Journal of medical genetics, 2000, 10.1136/jmg.37.12.947
  • The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group., , American journal of human genetics, 2000
  • Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics., , American journal of human genetics, 2000, 10.1086/302807
  • BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey., , Annals of the New York Academy of Sciences, 1998, 10.1111/j.1749-6632.1998.tb10828.x
  • Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators., , American journal of human genetics, 1998, 10.1086/301745
  • Localization of BRCA1 gene expression in adult cynomolgus monkey tissues., , The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 1997, 10.1177/002215549704500901
  • Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites., , Journal of medical genetics, 1996, 10.1136/jmg.33.10.814
  • Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13., , Genomics, 1996, 10.1006/geno.1996.0428
  • Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations., , Human molecular genetics, 1996, 10.1093/hmg/5.6.835
  • BRCA2 germline mutations in male breast cancer cases and breast cancer families., , Nature genetics, 1996, 10.1038/ng0596-123
  • The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds., , Nature genetics, 1996, 10.1038/ng0396-333
  • Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core., , Human mutation, 1996, 10.1002/humu.1380080102
  • Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21., , Genomics, 1995, 10.1006/geno.1995.1185
  • BRCA1 mutations in Ashkenazi Jewish women., , American journal of human genetics, 1995
  • Linkage analysis of 26 Canadian breast and breast-ovarian cancer families., , Human genetics, 1995, 10.1007/bf00223867
  • A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening., , JAMA, 1995, 10.1001/jama.1995.03520310033026
  • Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families., , Nature genetics, 1994, 10.1038/ng1294-392
  • The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21., , Human molecular genetics, 1994, 10.1093/hmg/3.9.1679
  • Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA., , Human molecular genetics, 1993, 10.1093/hmg/2.8.1193
  • VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis, , Bioinformatics, 1911, https://doi.org/10.1093/bioinformatics/btw826

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Steffany Grondin - Maitrîse avec mémoire - En cours
  • Gemma Montalban Canudas - Post-doctorat - En cours
  • Anne-Laure Renault - Maitrîse avec mémoire - 2014/01
  • Martin Leclerc - Doctorat - 2016/01
  • Mandy Ducy - Maitrîse avec mémoire - 2018/09
  • Audrey Lemaçon - Doctorat - 2019/01

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine,  local 4645
Québec, Québec G1V 0A6
Canada

Renseignements - Secrétariat :
vdres@fmed.ulaval.ca

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs